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In anticipation of the 2012 World
Health Report, this paper was commis-
sioned to help contextualize and critically
reflect on the theme of ‘‘no health without
research.’’
Why Do We Need Trials and
What Makes a Trial a Trial?
Clinical trials are needed globally to
reduce disease burdens by helping devel-
oping safe and effective new therapies and
vaccines. These solutions may be for non-
communicable diseases like cancer and
diabetes, or, as is especially needed in the
poorest regions of the world, infectious
disease. Developing countries are under-
represented in research due to lack of
commercial viability and trained research-
ers, yet it is in these poorest regions where
research-led solutions could bring the
greatest impact to high rates of early
mortality.
As a research tool clinical trials are
fundamental in the effort to develop new
products by gaining the data required by
regulators, whether for product license
extensions for existing therapies for com-
mon ailments or to bring cutting edge new
therapies and vaccines into approved use.
However, there is also a need for clinical
trials to bring evidence to determine how to
improve the management of health issues;
these studies often do not involve a
medicinal product but instead compare
different options, such as different types of
management of an illness in hospital with
community-based care. Or, for example, a
clinical trial might be used to assess different
mechanisms to improve patient adherence
to therapy. These pragmatic disease man-
agement trials can bring about significant
improvements in public health and often
require large yet simple trial designs.
The World Health Organization and
journal editors define clinical trials as ‘‘any
research study that prospectively assigns
human participants or groups of humans
to one or more health-related interven-
tions to evaluate the effects on health
outcomes’’ [1]. Patients may be rando-
mised to an intervention involving either
an investigational new product or the
standard-of-care treatment, or the patient
might be randomised to be cared for by
nurses who have been trained in one of
two or more comparative ways.
Why Go Global?
Clinical trial data are often collected
from varied populations to support a
license application because geographically
different trial sites are needed to ensure the
product is safe and works in the same way
in varying ethnic groups. This require-
ment is true whether it is a pharmaceutical
company working on the next blockbuster
drug or a non-for-profit partnership
(which typically have a pharmaceutical
partner involved in a non-for-profit ca-
pacity) developing a new drug or vaccine
for a neglected disease. Here scientific and
regulatory factors combine to encourage
the globalisation of clinical trials.
Clinical trials are also being conducted
across more diverse countries for econom-
ic reasons. Clinical trials are expensive and
are taking longer to conduct than in the
past, thus further compounding the in-
creased costs [2], and this is the case for all
types of trial, whether commercial or
academic. There are many reasons for
the increased cost and duration of clinical
trials, but it is a widely held view that
clinical regulations, or more precisely, the
interpretation and implementation of
these regulations, are a major factor [2].
Few would argue with the importance of
well-regulated clinical trials to ensure high
ethical standards and that trial conduct
and processes are producing valid and
accurate data. However, there is a call for
making trial regulation less complicated
and more readily adaptable to risk, and for
having guidelines that are globally appli-
cable and adaptable to all types of trial
[3,4]. Such guidelines would be as easily
applied to pragmatic trials of existing
treatments or disease management ques-
tions as they would be for trials of new
drugs and vaccines.
There are many justifiable reasons for
running clinical trials across multiple
countries and indeed continents, or even
only in sites that are not in the sponsor’s
location. Some countries are able to
recruit participants faster than others for
varied and valid reasons. The trial could
be for a rare health event, such as dengue
fever or traumatic cerebral hemorrhage,
and for these trials it is necessary to recruit
many centers in diverse locations, each site
perhaps recruiting just a few patients to
avoid prolonging the duration of the trial
and increasing the wait for lifesaving new
interventions. It is also true that some
regions of the globe are vastly more
expensive than others to conduct trials.
For example, a clinical trial in India can
cost one-tenth of the price that it would
cost in the US [5]. Since clinical trials costs
are largely driven by labour, much of these
savings are from lower salaries to physi-
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time and cost of developing drugs or
vaccine influences the final product cost
and return on investment, so the logic of
reducing trial costs is clear and reasonable.
What Are the Ethical, Scientific,
and Operational Challenges of
Running Trials across the
Globe?
Clinical trials should be designed, con-
ducted, and monitored in proportion to
their relative risk and complexity [6].
However, in developing countries it is
our experience that external sponsors and
their locally appointed contract research
organisations (CROs) are often overly
zealous in their interpretation of trial
guidelines and apply a one-size-fits-all
approach to trial coordination and mon-
itoring, irrespective of the risk and com-
plexity. This is often due to an inaccurate
perception from the sponsor and/or CRO
about the ability of the research sites to
run high quality and compliant trials. This
perspective can lead to overly cumber-
some trials and to burdening of research
sites with administrative requests and site
visits that are not necessary. In addition,
steps and processes are introduced that
can alter the expectations of ethics com-
mittees, funders, and reviewers and be-
come perpetuated, irrespective of the real
need. Many research teams in developing
countries do not have the experience to
question the necessity of these overly
stringent requirements, which therefore
remain in place and become the expected
norm for every clinical research study.
For example, some ethics committees
insist on Data Safety and Monitoring
Committees being put in place for every
trial even if these committees are not
needed or appropriate [7]. However, trials
groups often comply without challenging
the request, and the requirement becomes
a standard step in the process, without
examining each time whether it is appro-
priate for the specific protocol in question.
We are not suggesting in any way that
processes and standards should be lower
or different in developing countries, but
we do feel that overly cautious application
of regulations is common around the
world- and that it creates a greater burden
to research in resource-limited settings.
Table 1 provides examples of steps and
issues in clinical trial conduct that could be
adversely impacted by inappropriate inter-
pretation ofguidelines or overlykeen CROs
and sponsors. These steps are important for
optimum trial conduct and should be
carefully considered for each trial and its
specific risks and complexity. However,
overly ‘‘cooking’’ or implementing these
steps can unnecessarily overburden and
increase the cost of clinical trials, which
results in slowing new product development
and discourages investigators from conduct-
ing their own independent research.
In the US and the UK it is increasingly
recognised that trials have become too
expensive and bureaucratic, and initiatives
such as the Clinical Trial Transformation
Initiative [8] and the Medical Research
Council’s Methodology Research Hubs in
the UK are trying to rationalise design,
conduct, and regulation to improve clin-
ical trial design and make running them
easier, more attractive, and less expensive.
There is a danger that developing and
middle-income countries are not involved
in this emerging enthusiasm and effort to
make trial design more rational and
attractive to potential researchers.
It is essential to protect participants in
clinical trials from exploitation and this
needs particular care and thought in
developing countries where populations
can be more vulnerable. To achieve this
participant protection, great efforts have
been made in recent years to strengthen
ethical and regulatory review in develop-
ing countries, which is, of course, extreme-
ly necessary and important. However,
whilst in high-income countries efforts
have been made to streamline and simplify
ethics and the regulatory review process,
application to ethics committees has be-
come highly administrative in resource-
limited countries with increasing paper
work, and multiple sequential reviews are
often needed before a trial can start. This
administrative hurdle unfortunately fur-
ther discourages local academic research-
ers in developing countries [9]. More
wealthy foreign trial sponsors may well
have the capacity to resource the admin-
istrative burden of getting protocols
through these committees; however, low
investment and support for ethics and
regulatory committees in developing coun-
tries is a problem for external sponsors.
When international product development
efforts are delayed by slow review of trial
protocols, this seriously increases the time
it takes to develop new drugs and vaccines
for diseases of poverty such as tuberculosis
and malaria.
What Do We Need to Do
Differently?
Clinical trials have gone global and this
is certainly a good thing—on the whole.
Conducting varying types of trials in low-
and middle-income countries (LMICs) can
be very positive and the experience
research sites gain by working with
commercial or not-for-profit sponsors rais-
es research standards and brings health
improvements to developing countries and
badly needed investment to these research
institutions. Externally sponsored trials
also bring increasing capacity for research
through training and engagement in
product development and other global
public health initiatives.
However, the global research commu-
nity needs to improve efforts to support
and encourage investigators from LMICs
to seek to run their own trials. They need
to be provided with incentives and a
Summary Points
N Clinical trials are conducted across the globe for perfectly good reasons. This is
positive because populations in developing countries are under-represented in
research.
N Research sites in developing countries benefit from working with externally
sponsored clinical trials because they benefit from increased capacity
development and investment.
N Locally led research is becoming harder to undertake in developing countries
because of complex trial regulations and administrative burdens. There should
be a balance between local and externally led trials.
N There is a need for more trials that compare different approaches to managing
disease and health issues. This is especially true in low-income settings where
simple interventions could make significant improvements to health outcomes
if there was evidence to support implementation.
N Clinical trials operations should be specific to the risk and complexity of each
trial and not governed by one-size-fits-all requirements of sponsors and their
contracted organisations. Overly burdening trials with too-rigorous require-
ments is pushing up costs and putting off investigators to undertake research.
N Trials in low-income settings need to contribute to clinical trial methodology
research efforts.
PLoS Medicine | www.plosmedicine.org 2 June 2012 | Volume 9 | Issue 6 | e1001228Table 1. Areas of clinical trial conduct where overly cautious application of guidelines (‘‘guideline application creep’’) might be
problematic.
Areas of Clinical Trial Conduct Issues, Risks, or Cautions Advisory Notes
Clinical trial monitoring It is essential that steps are put in place to
ensure that clinical trials collect quality data
and are run to high ethical standards.
Trial monitoring should depend upon the risk and
complexity of the trial and not be a ‘‘one-size-fits-all’’
application of the common perception of ‘‘full’’ clinical
trial monitoring.
In some situations (often external sponsored trials)
monitoring is disproportionately zealous relative to
the nature of the trial and is unnecessarily
burdensome on the trial site.
The aim of a monitoring or quality management plan
should be to ensure the question is being answered
accurately and the rights and safety of the patients are
protected. All approaches can be assessed against this
pragmatic purpose.
In other circumstances (often academic trials) there is
not enough monitoring to ensure the data is being
captured accurately and that the participants’ rights
and safety are being protected.
There are many misconceptions about what is
needed and these fuel the above two issues of
over- and under-monitoring.
In low-income countries and other resource-limited
settings highly effective alternatives to commercial
monitoring are a very good solution. Examples include
training in-house monitoring and reciprocal monitoring
between research sites.
Data safety boards Sponsors and review boards are requesting DSMBs
for all clinical trials.
DSMBs are very important in many trials, such as blinded
trials where the question may be answered before the
end of the trial, or if there is any risk from an intervention.
Putting a DSMB in place where they are not needed
increases the cost of the trial and takes the time of
DSMB members where their expertise is in short supply,
especially in developing countries.
Some trials do not need a DSMB, such as very fast or
open trials, or trials with a low risk intervention.
In developing countries there is a lack of researchers
with the appropriate skills and experience to be
members of these committees, which is even more
reason to carefully consider whether they are needed.
Clinical trial laboratories Some sponsors are insisting on laboratory accreditation
and this is driving the belief from investigators that
there are some very arduous and expensive requirements
for clinical trial laboratories.
Laboratory measurements taken for use in clinical trial
need to be accurate and reliable. Simple measures and
processes can assure this.
Insisting on accreditation could push regulators in
regions to take the position that this is the norm and
necessary and insist on accredited laboratories for all trials.
Whilst positive for those that have it, accreditation is not
necessary and working toward Good Clinical Trial
Laboratory Practices is readily and inexpensively
achievable.
This will further inhibit locally led research and increase
the costs for everyone.
In developing countries laboratories are working together
to achieve international clinical trial standard laboratory
practices. This is easily done by laboratories sharing
quality standards, templates, and operating procedures.
Assent from children In many countries seeking assent from children to
take part in clinical trials is a legal requirement.
There is a need from multi-region social science and
ethnographic research into the appropriateness and
effectiveness of seeking assent from children to take part
in clinical research.
This may not be appropriate or meaningful where
autonomy for children is not normal; it is especially
important to consider this in developing countries.
Investigators should undergo community engagement to
assess what is locally appropriate and acceptable. Then
sponsors and regulators should respect these findings.
Clinical trial training It is important that all those working on a clinical
trial are appropriately trained so that they understand
the protocol and the trial procedures to ensure consistency,
compliance with the protocol, and high standards
There are no specific requirements or qualifications for
investigators or indeed clinical trial trainers.
Some sponsors and regulatory agencies insist on
specific training or accredited trainers.
Sponsors of trials need to ensure that investigators have
the appropriate experience and qualifications, but there
are no minimum requirements.
Similar to the situation with the laboratories, there
are no specific requirements for training or trainers.
Misconceptions about this are discouraging locally led
trials and raising the expectations of review committees.
Clinical trial training should be given by those with the
appropriate experience and training. This does not need
to be someone external to the research site or an outside
contractor.
Good Clinical Practice training is important for everyone
involved in a trial. Again this can be provided within
research sites by an experienced clinical trialist and does
not need to involve expensive organisations. There are
also plenty of high-quality free online courses available.
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health and employing institutions) to plan
their own studies and opportunities to
diversify beyond externally sponsored
trials. A good example of a local investi-
gator-led clinical trial is a recent study in
Sri Lanka that addressed a locally relevant
question—how to treat snakebites. Inter-
estingly it was advice from a journal’s
statistician that helped the investigators
demonstrate a life-saving intervention to
prevent allergic reactions to anti-venom
serum for snakebites, which is now being
widely used [10]. It is an example of a
pragmatic trial that used existing therapies
to solve a local issue. The fact that external
statistical support was needed shows how
capacity is limited and wide support and
collaboration are important.
Widespread disparities in clinical care,
scientific and health literacy, and econom-
ic and social development exist between
developed and developing countries.
These differences carry concerns about
exploitation exacerbated by the power gap
between patient-participants and physi-
cian-investigators. The vulnerability of
developing world patient-participants has
been discussed extensively in the past
decade [11].
When running trials in vulnerable
populations, such as rural communities in
developing countries, detailed consider-
ation needs to be given to engaging with
the community, explaining the research
that is planned, and then carefully select-
ing the most appropriate approaches for
seeking fully informed consent [12]. More
social science-based research is needed to
make sure that the best approaches,
messages, and methods are being prac-
ticed in order to protect the study
population (and wider community) and
also to ensure that the message is being
clearly explained and understood. Do
those giving consent really understand
what is being asked of them? Do they
understand that they have a choice; that
they are taking part in research and this
differs from standard care and, most
importantly, that they can say no?
Clinical trial methodology research is
needed because there are great differences
in cultures and perceptions across the
globe, and what is appropriate in one
place might not be in another, and so it
might not be appropriate to simply export
a requirement, and again for this require-
ment to become introduced unchecked
into becoming a standard requirement.
For example seeking assent from children
is a legal requirement in many countries.
Is it always appropriate to apply this rule
everywhere? Should a child be asked for
assent when they do not normally have
any autonomy?
There is a need for training and support
for clinical trial investigators and their
teams, as well as a need for strengthening
capacity for scientific and ethical review in
these regions. This capacity needs to be
cross-cutting and not focused on one
disease or protocol if it is to leave trial
sites with the skills and knowledge to run
their own studies [13]. New globally
appropriate guidelines for good clinical
practice would greatly benefit researchers
working in non-investigational product
trials irrespective of where they are in the
world. These guidelines need to be
informed by internationally based meth-
odology research.
Risk and complexity-based assessment
of trials would improve trial conduct,
reduce costs, and enable key elements
such as quality management to be more
likely to pick up real issues that impact
trial outcomes, rather than the one-size-
fits-all approach to clinical trial monitoring
(often described as ‘‘tick box checking’’)
[14].
We feel that pre-trial community en-
gagement, ongoing dialogue, and post-trial
information giving are important to build
and foster community trust for clinical
research. Researchers in the developing
world should come from the same or
similar community and relative standard
of living in which the research is being
done. Not only would mean they have a
sense of belonging to that community and
the country, but the country and the
community also would own and take pride
in their researchers. This relationship will
only work if the community receives and
perceives tangible and intangible benefits
from research. Post-trial access to medi-
cines and devices are an integral part of
this creation of trust between researchers
and the community. In the case of two
clinical trials in Sri Lanka, for example,
(one for a snakebite treatment and the
other a treatment for yellow oleander
poisoning [15,16]), the products are not
available locally because the costs are too
high.
In addition we all need to be watchful
about exporting mistakes made in the
northern hemisphere. Whilst the US and
Europe are examining how to encourage
more academic trials and limit bureau-
cracy, these same problems are being
applied with extra vigour in less experi-
enced settings. We have found that when
there is limited experience, those indi-
viduals tasked with reviewing research
opt for caution and ask for more rather
than less. Whilst this situation is correct
and understandable, it highlights the
need for research reviewers in develop-
ing countries to be better supported and
provided with the knowledge and confi-
d e n c et ok n o ww h i c hr e q u i r e m e n t st ob e
applied and when. The current excess of
caution is limiting research and making
trials more expensive and complex than
they need to be. The ramifications are
important; too few academic trials and
t h es l o wd e v e l o p m e n to fn e wd r u g sa n d
vaccines in regions of the world most
burdened by disease directly impact
efforts to reduce early mortality in
diseases of poverty.
Finally, the globalisation of clinical trials
should not be about running inexpensive
trial sites to benefit distant people, but
should focus on bringing research to
populations who have previously been
under-represented in clinical trials, and
enabling these same communities the
benefits resulting from new drugs, vac-
cines, and improvements in managing
health.
Table 1. Cont.
Areas of Clinical Trial Conduct Issues, Risks, or Cautions Advisory Notes
Trial networks in many low-income countries collaborate
to share training between their research sites; this is a
very effective and a credible mechanism for increasing
capacity.
DSMB, data safety and monitoring board.
doi:10.1371/journal.pmed.1001228.t001
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